title: [Monitoring of iatrogenic neutropenia: importance of the pharmacovigilance analysis].
authors.forename: Laure
authors.initials: L
authors.lastname: Peyro-Saint-Paul
authors.forename: Christophe
authors.initials: C
authors.lastname: Roberge
authors.forename: Valérie
authors.initials: V
authors.lastname: Auclair
authors.forename: Brigitte
authors.initials: B
authors.lastname: Mosquet
authors.forename: Catherine
authors.initials: C
authors.lastname: Guillemard
mesh_terms: D014150:Antipsychotic Agents / Q000009:adverse effects*; D000998:Antiviral Agents / Q000009:adverse effects*; D003024:Clozapine / Q000009:adverse effects*; D004347:Drug Interactions; D005602:France; D006526:Hepatitis C / Q000150:complications / Q000188:drug therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced* / Q000453:epidemiology*; D011358:Product Surveillance, Postmarketing; D012254:Ribavirin / Q000009:adverse effects*; D012563:Schizophrenia, Paranoid / Q000150:complications / Q000188:drug therapy
chemical_list: D014150:Antipsychotic Agents; D000998:Antiviral Agents; D012254:Ribavirin; D003024:Clozapine